Connect with us

International

‘Gaslighting’ Is The Word Of The Year For Good Reason

‘Gaslighting’ Is The Word Of The Year For Good Reason

Authored by Jeffrey Tucker via The Epoch Times,

Every year Merriam-Webster picks a…

Published

on

'Gaslighting' Is The Word Of The Year For Good Reason

Authored by Jeffrey Tucker via The Epoch Times,

Every year Merriam-Webster picks a word to capture the culture of a moment in time. The choice is based on the frequency and quantity of search as well as the departure from the norm. This year the choice seems perfect: gaslighting. It’s drawn from the 1944 film noir starring Charles Boyer and Ingrid Bergman.

Charles Boyer and Ingrid Bergman in “Gaslight” (1944). (Metro-Goldwyn-Mayer Inc.)

The term means to be subjected to extended psychological trickery to cause the victim to question his or own reality. In the film, Boyer plays a handsome stranger who meets the beautiful heiress Bergman on a foreign journey and they fall in love. He convinces her to marry and move back together to London to her family home, whereby he embarks upon a subtle campaign to convince her she is bonkers while he secretly searches the home for legacy jewels he intends to steal.

It’s painful to watch but the experience connects with our own as we watch mainstream media, see respectable scientists canceled for supposedly spreading disinformation, or when we watch a White House press conference. They try to convince us that they are normal and we are the crazy ones, probably guilty of wrongthink or not aware of the full facts. The more they insist on their version of truth, the more we are invited to see ourselves as nuts for failing to give them all the benefit of our doubt.

The film has this crucial moment when Bergman flips from believing that she is a broken spirit and confused person suddenly to realizing that she is the victim of an elaborate hoax. Once she realizes this, and all the pieces fall into place, she calls him out as a fraud and a thief. The film ends as this genre must in those days. He is arrested and the victim is made whole.

So it is for all of us over this past year, as vast numbers of people realize that we are being gaslit by major media, Big Tech, and government. We were told that we faced a crisis so grim and horrible that we had to surrender our freedoms in the name of pathogenic control, even though we could clearly read the data on the risk. They closed schools, businesses, and weekly worship and told us it was for our own good.

To this day, they won’t admit that they were wrong. They were gaslighting us the entire time.

Tellingly, last year’s word was vaccine. The year before was pandemic. So you see how this goes. Pandemic to vaccine to gaslight. Yep, that pretty well sums up the last three years in a nice narrative from beginning to end. One hopes that we are all now waking up to the scam that has been perpetuated on us.

The notion that it was the “worst pandemic in a hundred years” is certainly disputable. We still don’t have real clarity on precisely how many people died from COVID, and this confusion is due to vast false positives of PCR testing backed by subsidized and rampant death misclassification. To this day, we do not know precisely how many people died from COVID or merely with COVID, or even if they truly had symptomatic COVID at all. None of this do we know for sure.

Then we can talk about the vaccine, which was never sterilizing of the virus simply because it is not possible to create such a thing around a fast-mutating coronavirus, a fact which we knew long before the pandemic began. So they called it a vaccine and lied that it would prevent infection and stop transmission even though that was never possible. Once this became obvious, and the whole point of mandates disappeared, they demanded we get it anyway at the pain of losing our jobs.

Now we have major media outlets admitting that more people are dying with the vaccine than without. And yet we are supposed to move on with our lives as if no one ever said anything false. There are no regrets, no apologies, no admissions of guilt. Even now, foreign nationals cannot travel to the United States to see the Statue of Liberty without showing proof of vaccination!

In a word, we’ve been gaslit at every turn.

One hopes that Americans watching events in China today get the point. Zero COVID was never epidemiology. It was an ideology of totalitarianism, a great excuse to do to us what bad actors in tech, media, and government wanted to do anyway but could not get away with in normal times. China easily migrated from virus-control theater to full surveillance. Even now, the Chinese Communist Party (CCP) is combing through cell-phone data to ferret out political dissenters. The point is to punish in ways that were not possible decades ago.

Sadly, it will likely work. If your ability to work and live, and feed yourself and your family, are contingent on political obedience, the party in control enjoys more security in ways that dictators of old could only have dreamt.

The heck of it is that our own experience with virus control was in fact copied directly from the CCP model. In the third week of February 2020, Anthony Fauci sent his deputy assistant Clifford Lane on a WHO junket to Wuhan and other cities. The WHO produced a disgusting report that wholly recommended the China approach to the world. It said:

“Achieving China’s exceptional coverage with and adherence to these containment measures has only been possible due to the deep commitment of the Chinese people to collective action in the face of this common threat. At a community level this is reflected in the remarkable solidarity of provinces and cities in support of the most vulnerable populations and communities. Despite ongoing outbreaks in their own areas, Governors and Mayors have continued to send thousands of health care workers and tons of vital PPE supplies into Hubei province and Wuhan city.

“At the individual level, the Chinese people have reacted to this outbreak with courage and conviction. They have accepted and adhered to the starkest of containment measures—whether the suspension of public gatherings, the month-long ‘stay at home advisories or prohibitions on travel. Throughout an intensive 9-days of site visits across China, in frank discussions from the level of local community mobilizers and frontline health care providers to top scientists, Governors and Mayors, the Joint Mission was struck by the sincerity and dedication that each brings to this COVID-19 response.”

In a word, barf. Actually, Fauci, Lane, and everyone else involved in this gaslighting deserves full moral condemnation. They told us that the right way to manage a pandemic but their virus control very quickly and easily became political control.

This is true not only in China but also the United States. Early on, any protests against lockdowns were regarded not only as contrary to public health but also politically seditious. The media played along with this. And later with the vaccines, the refusal to get the shot was treated nearly as an act of treason.

Which is one of many problems with lockdowns. Not only do they not work at stopping the pathogen over the long term—at best they “slow the spread” for no good reason—but they intensify political control over society and attack fundamental rights and liberties. Fauci himself made frequent statements that disparaged the very idea of freedom itself, while meme culture jumped on the idea and started a deliberate misspelling: “freedumb.”

That movie “Gaslight” is a painful experience as the viewer watches a wretched man gradually crush the spirit of a sincere and trusting woman. It’s utterly abusive but at some point she wakes up to the racket and works to see justice done. So should we all.

Tyler Durden Tue, 11/29/2022 - 18:05

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

International

Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.

Published

on

Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 

Shutterstock

This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading

Trending